drug · antibody
tozorakimab
Phase 3updated 5mo agoby $AZN ASTRAZENECA PLC🔗 ChEMBL
Phase 3community read0 votes
🐶 often sniffed alongside
top 3Antibody drug with a maximum clinical stage of Phase 3 (across all indications), with 7 investigational indications.
all catalysts(1)
Trials studying tozorakimab
- phase3Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
- phase2Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids
- phase2A Study to Investigate Efficacy and Safety of Tozorakimab Injections Compared With Placebo in Adult Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations and Elevated Eosinophils
- phase3Long-term Safety and Tolerability of Tozorakimab in Patients With COPD and History of Exacerbations
- phase3Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
- phase3Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.
- phase3Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).
- phase1An Accessorised Prefilled Syringe to an Autoinjector Pharmacokinetic Bridging Study of Tozorakimab
News(4)
- STAT+: AstraZeneca’s experimental COPD treatment posts strong results in late-stage studiesAn experimental COPD drug from AstraZeneca could prove competitive with existing treatments, and have a slice of the market to itself.stat · 28d ago
- AZ's R&D chief Barr touts internal 'science success story' after IL-33 antibody's stellar showing in COPDWith a detailed data drop that AstraZeneca’s R&D chief describes as an internal “science success story,” the British Big Pharma has secured an FDA priority review for what it believes could become…fiercebiotech · 28d ago
- Earnings roundup: Biogen’s ‘resiliency,’ AstraZeneca’s growth pitch and GSK’s oncology pushBetter-than-expected sales helped Biogen regain the support of investors, while AstraZeneca and GSK worked to convince Wall Street that they can hit ambitious revenue targets.biopharma_dive · 2mo ago
- Wainua flop narrows AstraZeneca’s path to $80B goal ahead of high-risk readoutsWith a Phase 3 failure denting the rare disease drug’s prospects, AstraZeneca has little room for error as it plots a path toward its ambitious 2030 sales target.biospace · 2mo ago
Data sources
last refreshed 19m ago
Found something off?
comments(0)
5-min edit window · permanent after that